HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Copper-67

Also Known As:

67Cu radioisotope; Cu-67 radioisotope

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Isotopes: 4944
  - Radioisotopes: 14866
    - Copper Radioisotopes: 3
      - Copper-67: 9

Experts

1.	Peng, Fangyu: 1 article (04/2022)
2.	Buncic, Gojko: 1 article (10/2019)
3.	Cullinane, Carleen: 1 article (10/2019)
4.	Donnelly, Paul S: 1 article (10/2019)
5.	Haskali, Mohammad B: 1 article (10/2019)
6.	Hicks, Rodney J: 1 article (10/2019)
7.	McInnes, Lachlan E: 1 article (10/2019)
8.	Roselt, Peter D: 1 article (10/2019)
9.	Van Zuylekom, Jessica K: 1 article (10/2019)
10.	Waldeck, Kelly: 1 article (10/2019)

Related Diseases

1.	Urinary Bladder Neoplasms (Bladder Cancer) 01/01/2000 - "This study assessed the ability of copper-67 ((67)Cu)-C595 murine antimucin monoclonal antibody to bind selectively to superficial bladder tumors when administered intravesically, with a view to its development for therapy. " 01/01/2004 - "Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer." 04/01/1997 - "Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer."
2.	Neoplasms (Cancer) 10/14/2019 - "The high tumor uptake, low background, and prolonged tumor retention, even at 24 hours post injection, suggest the bivalent agent is a promising diagnostic for prostate cancer and could be used for prospective dosimetry for therapy with a copper-67 variant." 04/01/2022 - "Recent progress in production of therapeutic copper-67 radionuclide invites clinical research in use of theranostic pair of 64CuCl2 and 67CuCl2 for cancer imaging and radionuclide therapy." 02/11/2015 - "However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. "
3.	Prostatic Neoplasms (Prostate Cancer) 10/14/2019 - "The high tumor uptake, low background, and prolonged tumor retention, even at 24 hours post injection, suggest the bivalent agent is a promising diagnostic for prostate cancer and could be used for prospective dosimetry for therapy with a copper-67 variant."
4.	Ovarian Neoplasms (Ovarian Cancer) 01/15/2007 - "Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis."
5.	Neoplasm Metastasis (Metastasis) 01/15/2007 - "Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Radioisotopes (Radionuclides)
3.	Therapeutic Uses
4.	Radiopharmaceuticals
5.	Mucins
6.	Lym-1 monoclonal antibody
7.	N- 4- nitrobenzyl- 5- (4- carboxyphenyl)- 10,15,20- tris(4- sulfophenyl)porphine
8.	Yttrium-90
9.	Actinium-225
10.	Astatine-211

Related Therapies and Procedures

1.	Therapeutics
2.	Precision Medicine
3.	Salvage Therapy
4.	Radioimmunotherapy